NCT04189588 2023-10-06
versus
TerSera Therapeutics LLC
Phase 2 Completed
Clinical Trials
18 trialsNCT00493467 2022-09-15
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00070018 2022-01-11
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00562978 2021-06-18
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
City of Hope Medical Center
Phase 1/2 Completed
NCT00591630 2021-02-02
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00058422 2020-11-12
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00491491 2020-08-31
Zevalin-beam for Aggressive Lymphoma
Sheba Medical Center
Phase 3 Completed
NCT01490723 2020-05-05
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00732498 2019-09-04
ESHAP
University of Arizona
Phase 2 Completed
NCT01686165 2018-08-28
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
University of Arizona
Phase 2 Completed
NCT00695409 2018-07-06
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT00119392 2018-06-29
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00073957 2018-01-23
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00453102 2016-01-01
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
University of Miami
Phase 2 Completed
NCT01538472 2014-09-11
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00387023 2013-11-18
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
M.D. Anderson Cancer Center
Phase NA Completed